KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EBT: 2011-2024

Historic EBT for Sarepta Therapeutics (SRPT) over the last 14 years, with Dec 2024 value amounting to $260.8 million.

  • Sarepta Therapeutics' EBT fell 2924.76% to -$383.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$164.2 million, marking a year-over-year decrease of 363.88%. This contributed to the annual value of $260.8 million for FY2024, which is 150.14% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported EBT of $260.8 million as of FY2024, which was up 150.14% from -$520.1 million recorded in FY2023.
  • In the past 5 years, Sarepta Therapeutics' EBT registered a high of $260.8 million during FY2024, and its lowest value of -$690.0 million during FY2022.
  • Over the past 3 years, Sarepta Therapeutics' median EBT value was -$520.1 million (recorded in 2023), while the average stood at -$316.4 million.
  • In the last 5 years, Sarepta Therapeutics' EBT slumped by 64.69% in 2022 and then soared by 150.14% in 2024.
  • Yearly analysis of 5 years shows Sarepta Therapeutics' EBT stood at -$553.1 million in 2020, then grew by 24.25% to -$418.9 million in 2021, then plummeted by 64.69% to -$690.0 million in 2022, then grew by 24.62% to -$520.1 million in 2023, then soared by 150.14% to $260.8 million in 2024.